Cameron John Reynolds Buys 181,818 Shares of VolitionRx Limited (NYSE:VNRX) Stock

VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds acquired 181,818 shares of VolitionRx stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $0.55 per share, with a total value of $99,999.90. Following the purchase, the chief executive officer now directly owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

VolitionRx Stock Performance

VNRX stock opened at $0.55 on Friday. The company has a market capitalization of $50.97 million, a price-to-earnings ratio of -1.53 and a beta of 1.09. VolitionRx Limited has a fifty-two week low of $0.43 and a fifty-two week high of $1.02. The stock has a fifty day moving average of $0.59 and a 200-day moving average of $0.64.

Analyst Ratings Changes

A number of brokerages recently weighed in on VNRX. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a report on Thursday, March 20th. StockNews.com assumed coverage on shares of VolitionRx in a research note on Friday. They set a “sell” rating for the company.

Institutional Trading of VolitionRx

Several hedge funds and other institutional investors have recently modified their holdings of the business. Northern Trust Corp grew its stake in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares in the last quarter. Two Sigma Securities LLC purchased a new position in shares of VolitionRx in the fourth quarter valued at $29,000. Millennium Management LLC purchased a new position in shares of VolitionRx in the fourth quarter valued at $36,000. Geode Capital Management LLC lifted its holdings in VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. lifted its holdings in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.